Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction

Journal of Surgical Oncology
Wen-Juan TianRong-Yu Zang

Abstract

Recent retrospective trials stated that a benefit of surgery for recurrent ovarian cancer may be limited to patients in whom a complete cytoreduction (R0) could be achieved. Most of them pointed out there was no difference in survival between residual disease of 0.1-1 cm (R1) and >1 cm (R2). The aim of this study was to evaluate survival benefits from cytoreduction to R1. Between 2002 and 2006, 123 patients with recurrent epithelial ovarian cancer undergoing secondary cytoreduction were identified from tumor registry databases. The median age at recurrence was 51 years (range: 28-84). Fifty-one (41.5%) patients had R0, 46 (37.4%) patients had R1, and 26 (21.1%) patients had R2 resection. The median survival of the entire cohort was 31.7 months, with an estimated 5-year survival of 31.1%. The median survival and estimated 5-year survival for patients with R1 were 31.1 months and 23.9%, and there were significant differences in survival when compared to 15.6 months and 6.4% in R2 (chi(2) = 7.45, P = 0.006), 63.2 months (mean survival) and 54.4% in complete cytoreduction (chi(2) = 8.93, P = 0.0028). Complete secondary cytoreduction is the strongest survival determinant in recurrent epithelial ovarian cancer, whereas patients with ...Continue Reading

References

Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G A OmuraR Mortel
Oct 6, 1999·European Journal of Obstetrics, Gynecology, and Reproductive Biology·G CormioL Selvaggi
Jun 8, 2002·Obstetrics and Gynecology·Eng Hseon TayNeville F Hacker
Jan 12, 2005·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·B GronlundC Høgdall
Jan 4, 2006·American Journal of Obstetrics and Gynecology·Ali AyhanTurkan Kucukali
Sep 30, 2006·Annals of Surgical Oncology·Philipp HarterUNKNOWN AGO Ovarian Cancer Study Group
Jan 2, 2007·Annals of Surgical Oncology·Pierluigi Benedetti PaniciRoberto Angioli
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William E WinterUNKNOWN Gynecologic Oncology Group Study
Aug 30, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H OksefjellC Tropé

❮ Previous
Next ❯

Citations

Aug 25, 2012·Current Oncology Reports·Philipp HarterAndreas du Bois
Aug 11, 2010·Annals of Surgical Oncology·Christina FotopoulouJalid Sehouli
Mar 15, 2013·JSLS : Journal of the Society of Laparoendoscopic Surgeons·Farr R NezhatPrakash Saharia
Jul 23, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·L Gonzalez BayonJ L Garcia Sabrido
Mar 16, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J TangR Y Zang
Dec 13, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S PignataF Heitz
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Thuria Al RawahiKhadra Galaal
Jan 12, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Juan Luis AlcázarMatías Jurado
Jan 29, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tomoko GotoKenichi Furuya
Sep 2, 2011·Women's Health·Florian HeitzPhilipp Harter
Jan 25, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Enora LaasElisabeth Chéreau
Oct 9, 2018·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Olivia Le SauxNaoual Bakrin
Oct 18, 2015·International Journal of Clinical Oncology·Takeo MinaguchiHiroyuki Yoshikawa
Apr 28, 2011·Molecular Imaging·Lucia M A CraneGooitzen M van Dam
Nov 18, 2020·Journal of Hepato-biliary-pancreatic Sciences·Masakazu YamamotoTadahiro Takada
Apr 8, 2020·Respiratory Medicine Case Reports·Eri InoueYoshiteru Morio
Jun 18, 2019·American Journal of Obstetrics and Gynecology·Allison GockleyAlexi A Wright
Jul 9, 2010·Journal of Gynecologic Oncology·Karin K Shih, Dennis S Chi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.